Autonomous Therapeutics
Autonomous Therapeutics develops next-generation nucleic acid medicines that are designed to be target-activated and variant-agnostic, aiming to address infectious diseases and metastatic cancers. The company integrates synthetic biology, nucleic acid chemistry, and advanced delivery platforms to create therapeutics that activate only in diseased cells. Operating from a 20,000 sq ft R&D facility in Rockville, MD, the team consists of multidisciplinary scientists and engineers focused on delivering resistance-proof, precision medicines.
Industries
N/A
Autonomous Therapeutics
Expertise Areas
- Nucleic acid therapeutic development
- Synthetic biology
- Oligonucleotide chemistry
- Analytical chemistry for therapeutics
Key Technologies
- Solid-phase oligonucleotide synthesis
- Bioconjugation chemistry
- Analytical methodologies (LC-MS, HPLC, chromatography)
- Inhalable drug formulation
Key People
CEO & Founder
Chief Scientific Officer
President of R&D, Co-founder
CEO & Founder
Chief Scientific Officer
President of R&D, Co-founder
News & Updates
Received $1 million award in a major public-private initiative for development of single-dose, broad-spectrum prophylactics.
Chosen for the Blue Knight initiative, supporting innovation for health security through joint government and industry collaboration.
Discussion of resistance-proof, adaptable nucleic acid platforms and regulatory progress for platform-based pandemic response.
Interview covering company growth, platform technologies, and expansion to Rockville.
Interview about mRNA therapeutic advances and broad applications from COVID-19 to cancers.
Selected for participation in DARPA’s PREEMPT program, addressing containment of viral diseases at the animal reservoir stage.
Received $1 million award in a major public-private initiative for development of single-dose, broad-spectrum prophylactics.
Chosen for the Blue Knight initiative, supporting innovation for health security through joint government and industry collaboration.
Discussion of resistance-proof, adaptable nucleic acid platforms and regulatory progress for platform-based pandemic response.
Interview covering company growth, platform technologies, and expansion to Rockville.
Interview about mRNA therapeutic advances and broad applications from COVID-19 to cancers.
Selected for participation in DARPA’s PREEMPT program, addressing containment of viral diseases at the animal reservoir stage.